REPORT SCOPE & OVERVIEW
The Next Generation Sequencing Market size was estimated USD 6.8 billion in 2022 and is expected to reach USD 32.7 billion by 2030 at a CAGR of 21.7% during the forecast period of 2023-2030.
Next Generation Sequencing (NGS), a high-throughput DNA sequencing method, which isolates billions or millions of DNA strands and simultaneously reads them, generating more data and eliminating the need for fragment-cloning methods (Sanger sequencing of genomes). NGS read duration are shorter than Sanger read times, but, because the signal to noise ratio increases with read length. NGS makes it possible to simultaneously check for changes in a wide range of genes.
MARKET DYNAMICS
DRIVERS
Advancements in NGS platforms
The recent introduction of new technology by major market players gives competitors an immediate competitive advantage. Players in the market are now concentrating on stepping up their R&D efforts in the creation of new Products & Services. The leading cutting-edge systems on the market are PromethlON (Oxford Nanopore Technologies), lon Torrent Genexus Dx Integrated Sequencer (Thermo Fisher), iSeq 100 (Illumina), and lon GeneStudio $5 System (Thermo Fisher).
RESTRAIN
Financial restrictions for consumers in developing nations
In underdeveloped countries, financing for academic R&D is primarily provided by outside sources. Various research and academic institutions are struggling with budget restrictions when it comes to the purchase and usage of cutting-edge and expensive equipment and technologies, despite continued efforts by governmental and commercial organizations to finance research globally. As a result, the construction and expansion of cutting-edge research facilities in academic and research institutions in poor countries is hindered. The implementation of technologies like NGS in poor countries in Asia and Africa is significantly hampered by this.
OPPORTUNITY
Application of NGS in molecular diagnostics and precision medicine
The effectiveness of biomarkers in illness identification has risen as a result of ongoing advancements in sequencing technologies and a deeper understanding of genetics. Governments around the world are anticipated to make sizeable investments in genome sciences, which will ensure a positive future demand for NGS in such applications. Precise diagnosis and personalized medicine increase survival rates and reduce the financial burden on national health insurance programs.
CHALLENGES
The storage, processing, and interpretation of the massive amounts of data produced by next-generation sequencing
NGS still presents great obstacles in terms of data storage, application, quality control administration, and interpretation, which slows the transition from the bench to the bedside in spite of enormous breakthroughs to widen NGS applications from research to clinic.
IMPACT OF RUSSIAN UKRAINE WAR
The Russian-Ukrainian conflict has had a substantial impact on the linkages within the global supply chain and the system of raw material prices. In Ukraine, which has roughly 2,530 facilities with the capacity to conduct international trials, about 510 clinical studies are carried out each year. According to the FDA clinical trials database in the US, 253 drugs and devices were undergoing clinical trials with at least one location in Ukraine prior to Russia's invasion of that country. The drugs and devices being tested in clinical trials during this battle have a substantial impact on the market for next-generation sequencing.
IMPACT OF ONGOING RECESSION
The company mission-driven culture and the Practical Process Improvement (PPI) Business System were key contributors to our success. In a year marked by supply-chain disruptions on a global scale, the conflict in the Ukraine, COVID-19 lockdowns in China, and inflationary headwinds, PPI allowed us to engage and empower our global colleagues to continually find new and improved ways to overcome obstacles, enhance workflows, and work more productively and effectively. This significantly impacted our capacity to satisfy customer demands, increase return on investments, spur growth, and carry out our mission, allowing us to provide differentiating performance for our stakeholders.
KEY SEGMENTS
By Product
Consumables
Sample Preparation
Target Enrichment
Others
Platforms
Sequencing
Data Analysis
In 2022, consumables segment is expected to held the highest market share of 74.7% in during the forecast period due to the consumables are used often and in high demand in both commercial and research applications of NGS, this segment has a bigger share and is growing at an exponential rate. These consumables include kits for target enrichment as well as kits for sample preparation. Since the majority of pharmaceutical businesses and research institutions are using NGS for a variety of diagnostic applications and cancer research, the usage of NGS consumables has expanded.
By Technology
WGS
Whole Exome Sequencing
Targeted Sequencing & Resequencing
DNA-based
RNA-based
In 2022, targeted sequencing & resequencing segment is expected to dominate the market share of 73.1% during the forecast period. Due to the need to examine a significant amount of whole genome data at specific gene sites and separated genetic expressions, this market is predicted to experience increased demand as whole genome sequencing becomes more popular. The NGS market is flooded with businesses that provide targeted sequencing services. As a result, during the projected period, this segment is anticipated to increase with WGS.
By Workflow
Pre-Sequencing
NGS Library Preparation Kits
Semi-automated Library Preparation
Automated Library Preparation
Sequencing
NGS Data Analysis
NGS Primary Data Analysis
NGS Secondary Data Analysis
NGS Tertiary Data Analysis
By Application
Oncology
Diagnostics and Screening
Oncology Screening
Sporadic Cancer
Inherited Cancer
Companion Diagnostics
Other Diagnostics
Research Studies
Clinical Investigation
Infectious Diseases
Inherited Diseases
Idiopathic Diseases
Non-Communicable/Other Diseases
ReProduct & Serviceive Health
NIPT
Aneuploidy
Microdeletions
PGT
Newborn Genetic Screening
Single Gene Analysis
HLA Typing/Immune System Monitoring
Metagenomics
Epidemiology & Drug Development
Agrigenomics & Forensics
Consumer Genomics
In 2022, oncology segment is expected to dominate the market share of 27.8% during the forecast period owing to the use of NGS for DNA & RNA sequencing, epigenetics, and analyzing chromosomal abnormalities accounts for over three-fourths of the global sequencing data, and these applications are what account for the high market share. A steadily rising prevalence of cancer necessitates the use of the most recent technology to help oncologists better understand the mechanics of cancer and tumor cells. Companies like Myriad offer genetic testing to help patients learn if they are more likely than others to acquire particular cancers in the future.
By End User
Academic Research
Clinical Research, Hospitals & Clinics
Pharma & Biotech Entities
Other Users
.png)
In 2022, the academic research segment is expected to dominate the market growth of 53.7% during the forecast period due to the use of NGS technologies in research initiatives conducted in universities and research facilities. Furthermore, it is projected that the availability of scholarships for PhD research in NGS would increase demand for NGS products and services, leading to profitable growth during the forecast period. In the upcoming years, it is also anticipated that offering on-site bioinformatics training would increase revenue from the academic research sector. These courses will include workshops on the actual implementation of NGS sequencing and data processing.
REGIONAL COVERAGE
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
REGIONAL ANALYSES
North America held a significant market share growing with a CAGR of 49.4% in 2022. Due to the numerous clinical laboratories that use NGS to deliver genetic testing services are what are driving the North America market. Furthermore, the region's development of WGS is anticipated to play a crucial role in the expansion the market. Also, due to the presence of significant R&D investment and the availability of a technologically cutting-edge healthcare research framework.
Asia-Pacific is witness to expand fastest CAGR rate during the forecast period due to the presence of significant developments by China and Japan for the technological integration of NGS methodologies and the development of healthcare, R&D, and clinical development frameworks in emerging economies like India and Australia.
Key Players
The major key players are Illumina, F. Hoffman-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies, PierianDx, Genomatix GmbH, DNASTAR, Inc., Perkin Elmer, Inc., Eurofins GATC Biotech GmbH, BGI, and Others.
RECENT DEVELOPMENT
Oxford Nanopore Technologies Plc, in June 2023, A scalable software solution for enhancing next-generation nanopore sequencing technology was unveiled by Oxford Nanopore Technologies Plc, a firm that develops nanopore sequencing technology, in collaboration with Geneyx, an AI platform. As a result, hospitals and other health facilities, such as genetic laboratories, will have access to analytical information about genome sequencing.
QIAGEN N.V, in March 2023, the development of a companion diagnostic trial for the isocitrate dehydrogenase-1 (IDH 1) inhibitor TIBSOVO® will be supported by a strategic cooperation between Servier, a major pharmaceutical firm, and QIAGEN N.V., a global provider of molecular sample insights. QIAGEN will validate these for identifying IDH 1 gene mutations among AML patients, including next-generation sequencing and a polymerase chain reaction.
Illumina (US) and GenoScreen (France), in October 2022, Illumina and GenoScreen partnered to increase access to genomic testing for multi-drug resistant tuberculosis in the tuberculosis-endemic nations.
| Report Attributes | Details |
| Market Size in 2022 | US$ 6.8 Billion |
| Market Size by 2030 | US$ 32.7 Billion |
| CAGR | CAGR of 21.7% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2019-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product & Service (Consumables, Platforms, & Services) • By Technology (WGS, Whole Exome Sequencing, Targeted Sequencing & Resequencing) • By Application (Oncology, Clinical Investigation, ReProduct & Serviceive Health, HLA Typing/Immune System Monitoring, Metagenomics, Epidemiology & Drug Development, Agrigenomics & Forensics, Consumer Genomics) • By End User (Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities, Other Users) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Illumina, F. Hoffman-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies, PierianDx, Genomatix GmbH, DNASTAR, Inc., Perkin Elmer, Inc., Eurofins GATC Biotech GmbH, BGI |
| Key Drivers | • Advancements in NGS platforms |
| Market Challenges | • The storage, processing, and interpretation of the massive amounts of data produced by next-generation sequencing |
Ans: The Next Generation Sequencing Market is expected to grow at 21.7% CAGR from 2023 to 2030.
Ans: According to our analysis, the Next Generation Sequencing Market is anticipated to reach USD 32.7 billion By 2030.
Ans: The leading participants are Illumina, F. Hoffman-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies, PierianDx, Genomatix GmbH, DNASTAR, Inc., Perkin Elmer, Inc., Eurofins GATC Biotech GmbH, BGI, and Others.
Ans: Yes, you may request customization based on your company's needs.
Ans: Factors such as the rise in research and development activities utilizing NGS technologies, increasing uses of NGS in clinical diagnosis, and discovery applications that require next-generation sequencing (NGS) technology.
TABLE OF CONTENT
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Next Generation Sequencing Market Segmentation, By Product
8.1 Consumables
8.1.1 Sample Preparation
8.1.2 Target Enrichment
8.1.3 Others
8.2 Platforms
8.2.1 Sequencing
8.2.2 Data Analysis
9. Next Generation Sequencing Market Segmentation, By Technology
9.1 WGS
9.2 Whole Exome Sequencing
9.3 Targeted Sequencing & Resequencing
9.3.1 DNA-based
9.3.2 RNA-based
10.Next Generation Sequencing Market Segmentation, By Workflow
10.1 Pre-Sequencing
10.1.1 NGS Library Preparation Kits
10.1.2 Semi-automated Library Preparation
10.1.3 Automated Library Preparation
10.2 Sequencing
10.3 NGS Data Analysis LED
10.3.1 NGS Primary Data Analysis
10.3.2 NGS Secondary Data Analysis
10.3.3 NGS Tertiary Data Analysis
11. Next Generation Sequencing Market Segmentation, By Application
11.1 Oncology
11.1.1 Diagnostics and Screening
11.1.1.1 Sporadic Cancer
11.1.1.2 Inherited Cancer
11.1.2 Companion Diagnostics
11.1.3 Other Diagnostics
11.2 Others
11.3 Clinical Investigation
11.3.1 Infectious Diseases
11.3.2 Inherited Diseases
11.3.3 Idiopathic Diseases
11.3.4 Non-Communicable/Other Diseases
11.4 Reproductive Health
11.4.1 NIPT
11.4.1.1 Aneuploidy
11.4.1.2 Microdeletions
11.4.2 PGT
11.4.3 Newborn Genetic Screening
11.4.4 Single Gene Analysis
11.5 HLA Typing/Immune System Monitoring
11.6 Metagenomics
11.7 Epidemiology & Drug Development
11.8 Agrigenomics & Forensics
11.9 Consumer Genomics
12. Next Generation Sequencing Market Segmentation, By End User
12.1 Academic Research
12.2 Clinical Research
12.3 Hospitals & Clinics
12.4 Pharma & Biotech Entities
12.5 Other Users
13. Regional Analysis
13.1 Introduction
13.2 North America
13.2.1 North America Next Generation Sequencing Market by Country
13.2.2 North America Next Generation Sequencing Market by Product & Service
13.2.3 North America Next Generation Sequencing Market by Technology
13.2.4 North America Next Generation Sequencing Market by Application
13.2.5 North America Next Generation Sequencing Market by End User
13.2.6 USA
13.2.6.1 USA Next Generation Sequencing Market by Product & Service
13.2.6.2 USA Next Generation Sequencing Market by Technology
13.2.6.3 USA Next Generation Sequencing Market by Application
13.2.6.4 USA Next Generation Sequencing Market by End User
13.2.7 Canada
13.2.7.1 Canada Next Generation Sequencing Market by Product & Service
13.2.7.2 Canada Next Generation Sequencing Market by Technology
13.2.7.3 Canada Next Generation Sequencing Market by Application
13.2.7.4 Canada Next Generation Sequencing Market by End User
13.2.8 Mexico
13.2.8.1 Mexico Next Generation Sequencing Market by Product & Service
13.2.8.2 Mexico Next Generation Sequencing Market by Technology
13.2.8.3 Mexico Next Generation Sequencing Market by Application
13.2.8.4 Mexico Next Generation Sequencing Market by End User
13.3 Europe
13.3.1 Eastern Europe
13.3.1.1 Eastern Europe Next Generation Sequencing Market by Country
13.3.1.2 Eastern Europe Next Generation Sequencing Market by Product & Service
13.3.1.3 Eastern Europe Next Generation Sequencing Market by Technology
13.3.1.4 Eastern Europe Next Generation Sequencing Market by Application
13.3.1.5 Eastern Europe Next Generation Sequencing Market by End User
13.3.1.6 Poland
13.3.1.6.1 Poland Next Generation Sequencing Market by Product & Service
13.3.1.6.2 Poland Next Generation Sequencing Market by Technology
13.3.1.6.3 Poland Next Generation Sequencing Market by Application
13.3.1.6.4 Poland Next Generation Sequencing Market by End User
13.3.1.7 Romania
13.3.1.7.1 Romania Next Generation Sequencing Market by Product & Service
13.3.1.7.2 Romania Next Generation Sequencing Market by Technology
13.3.1.7.3 Romania Next Generation Sequencing Market by Application
13.3.1.7.4 Romania Next Generation Sequencing Market by End User
13.3.1.8 Hungary
13.3.1.8.1 Hungary Next Generation Sequencing Market by Product & Service
13.3.1.8.2 Hungary Next Generation Sequencing Market by Technology
13.3.1.8.3 Hungary Next Generation Sequencing Market by Application
13.3.1.8.4 Hungary Next Generation Sequencing Market by End User
13.3.1.9 Turkey
13.3.1.9.1 Turkey Next Generation Sequencing Market by Product & Service
13.3.1.9.2 Turkey Next Generation Sequencing Market by Technology
13.3.1.9.3 Turkey Next Generation Sequencing Market by Application
13.3.1.9.4 Turkey Next Generation Sequencing Market by End User
13.3.1.10 Rest of Eastern Europe
13.3.1.10.1 Rest of Eastern Europe Next Generation Sequencing Market by Product & Service
13.3.1.10.2 Rest of Eastern Europe Next Generation Sequencing Market by Technology
13.3.1.10.3 Rest of Eastern Europe Next Generation Sequencing Market by Application
13.3.1.10.4 Rest of Eastern Europe Next Generation Sequencing Market by End User
13.3.2 Western Europe
13.3.2.1 Western Europe Next Generation Sequencing Market by Country
13.3.2.2 Western Europe Next Generation Sequencing Market by Product & Service
13.3.2.3 Western Europe Next Generation Sequencing Market by Technology
13.3.2.4 Western Europe Next Generation Sequencing Market by Application
13.3.2.5 Western Europe Next Generation Sequencing Market by End User
13.3.2.6 Germany
13.3.2.6.1 Germany Next Generation Sequencing Market by Product & Service
13.3.2.6.2 Germany Next Generation Sequencing Market by Technology
13.3.2.6.3 Germany Next Generation Sequencing Market by Application
13.3.2.6.4 Germany Next Generation Sequencing Market by End User
13.3.2.7 France
13.3.2.7.1 France Next Generation Sequencing Market by Product & Service
13.3.2.7.2 France Next Generation Sequencing Market by Technology
13.3.2.7.3 France Next Generation Sequencing Market by Application
13.3.2.7.4 France Next Generation Sequencing Market by End User
13.3.2.8 UK
13.3.2.8.1 UK Next Generation Sequencing Market by Product & Service
13.3.2.8.2 UK Next Generation Sequencing Market by Technology
13.3.2.8.3 UK Next Generation Sequencing Market by Application
13.3.2.8.4 UK Next Generation Sequencing Market by End User
13.3.2.9 Italy
13.3.2.9.1 Italy Next Generation Sequencing Market by Product & Service
13.3.2.9.2 Italy Next Generation Sequencing Market by Technology
13.3.2.9.3 Italy Next Generation Sequencing Market by Application
13.3.2.9.4 Italy Next Generation Sequencing Market by End User
13.3.2.10 Spain
13.3.2.10.1 Spain Next Generation Sequencing Market by Product & Service
13.3.2.10.2 Spain Next Generation Sequencing Market by Technology
13.3.2.10.3 Spain Next Generation Sequencing Market by Application
13.3.2.10.4 Spain Next Generation Sequencing Market by End User
13.3.2.11 Netherlands
13.3.2.11.1 Netherlands Next Generation Sequencing Market by Product & Service
13.3.2.11.2 Netherlands Next Generation Sequencing Market by Technology
13.3.2.11.3 Netherlands Next Generation Sequencing Market by Application
13.3.2.11.4 Netherlands Next Generation Sequencing Market by End User
13.3.2.12 Switzerland
13.3.2.13.1 Switzerland Next Generation Sequencing Market by Product & Service
13.3.2.13.2 Switzerland Next Generation Sequencing Market by Technology
13.3.2.13.3 Switzerland Next Generation Sequencing Market by Application
13.3.2.13.4 Switzerland Next Generation Sequencing Market by End User
13.3.2.13 Austria
13.3.2.13.1 Austria Next Generation Sequencing Market by Product & Service
13.3.2.13.2 Austria Next Generation Sequencing Market by Technology
13.3.2.13.3 Austria Next Generation Sequencing Market by Application
13.3.2.13.4 Austria Next Generation Sequencing Market by End User
13.3.2.14 Rest of Western Europe
13.3.2.14.1 Rest of Western Europe Next Generation Sequencing Market by Product & Service
13.3.2.14.2 Rest of Western Europe Next Generation Sequencing Market by Technology
13.3.2.14.3 Rest of Western Europe Next Generation Sequencing Market by Application
13.3.2.14.4 Rest of Western Europe Next Generation Sequencing Market by End User
13.4 Asia-Pacific
13.4.1 Asia Pacific Next Generation Sequencing Market by Country
13.4.2 Asia Pacific Next Generation Sequencing Market by Product & Service
13.4.3 Asia Pacific Next Generation Sequencing Market by Technology
13.4.4 Asia Pacific Next Generation Sequencing Market by Application
13.4.5 Asia Pacific Next Generation Sequencing Market by End User
13.4.6 China
13.4.6.1 China Next Generation Sequencing Market by Product & Service
13.4.6.2 China Next Generation Sequencing Market by Technology
13.4.6.3 China Next Generation Sequencing Market by Application
13.4.6.4 China Next Generation Sequencing Market by End User
13.4.7 India
13.4.7.1 India Next Generation Sequencing Market by Product & Service
13.4.7.2 India Next Generation Sequencing Market by Technology
13.4.7.3 India Next Generation Sequencing Market by Application
13.4.7.4 India Next Generation Sequencing Market by End User
13.4.8 Japan
13.4.8.1 Japan Next Generation Sequencing Market by Product & Service
13.4.8.2 Japan Next Generation Sequencing Market by Technology
13.4.8.3 Japan Next Generation Sequencing Market by Application
13.4.8.4 Japan Next Generation Sequencing Market by End User
13.4.9 South Korea
13.4.9.1 South Korea Next Generation Sequencing Market by Product & Service
13.4.9.2 South Korea Next Generation Sequencing Market by Technology
13.4.9.3 South Korea Next Generation Sequencing Market by Application
13.4.9.4 South Korea Next Generation Sequencing Market by End User
13.4.10 Vietnam
13.4.10.1 Vietnam Next Generation Sequencing Market by Product & Service
13.4.10.2 Vietnam Next Generation Sequencing Market by Technology
13.4.10.3 Vietnam Next Generation Sequencing Market by Application
13.4.10.4 Vietnam Next Generation Sequencing Market by End User
13.4.11 Singapore
13.4.11.1 Singapore Next Generation Sequencing Market by Product & Service
13.4.11.2 Singapore Next Generation Sequencing Market by Technology
13.4.11.3 Singapore Next Generation Sequencing Market by Application
13.4.11.4 Singapore Next Generation Sequencing Market by End User
13.4.12 Australia
13.4.13.1 Australia Next Generation Sequencing Market by Product & Service
13.4.13.2 Australia Next Generation Sequencing Market by Technology
13.4.13.3 Australia Next Generation Sequencing Market by Application
13.4.13.4 Australia Next Generation Sequencing Market by End User
13.4.13 Rest of Asia-Pacific
13.4.13.1 Rest of Asia-Pacific Next Generation Sequencing Market by Product & Service
13.4.13.2 Rest of Asia-Pacific Next Generation Sequencing Market by Technology
13.4.13.3 Rest of Asia-Pacific Next Generation Sequencing Market by Application
13.4.13.4 Rest of Asia-Pacific Next Generation Sequencing Market by End User
13.5 Middle East & Africa
13.5.1 Middle East
13.5.1.1 Middle East Next Generation Sequencing Market by country
13.5.1.2 Middle East Next Generation Sequencing Market by Product & Service
13.5.1.3 Middle East Next Generation Sequencing Market by Technology
13.5.1.4 Middle East Next Generation Sequencing Market by Application
13.5.1.5 Middle East Next Generation Sequencing Market by End User
13.5.1.6 UAE
13.5.1.6.1 UAE Next Generation Sequencing Market by Product & Service
13.5.1.6.2 UAE Next Generation Sequencing Market by Technology
13.5.1.6.3 UAE Next Generation Sequencing Market by Application
13.5.1.6.4 UAE Next Generation Sequencing Market by End User
13.5.1.7 Egypt
13.5.1.7.1 Egypt Next Generation Sequencing Market by Product & Service
13.5.1.7.2 Egypt Next Generation Sequencing Market by Technology
13.5.1.7.3 Egypt Next Generation Sequencing Market by Application
13.5.1.7.4 Egypt Next Generation Sequencing Market by End User
13.5.1.8 Saudi Arabia
13.5.1.8.1 Saudi Arabia Next Generation Sequencing Market by Product & Service
13.5.1.8.2 Saudi Arabia Next Generation Sequencing Market by Technology
13.5.1.8.3 Saudi Arabia Next Generation Sequencing Market by Application
13.5.1.8.4 Saudi Arabia Next Generation Sequencing Market by End User
13.5.1.9 Qatar
13.5.1.9.1 Qatar Next Generation Sequencing Market by Product & Service
13.5.1.9.2 Qatar Next Generation Sequencing Market by Technology
13.5.1.9.3 Qatar Next Generation Sequencing Market by Application
13.5.1.9.4 Qatar Next Generation Sequencing Market by End User
13.5.1.10 Rest of Middle East
13.5.1.10.1 Rest of Middle East Next Generation Sequencing Market by Product & Service
13.5.1.10.2 Rest of Middle East Next Generation Sequencing Market by Technology
13.5.1.10.3 Rest of Middle East Next Generation Sequencing Market by Application
13.5.1.10.4 Rest of Middle East Next Generation Sequencing Market by End User
13.5.2. Africa
13.5.2.1 Africa Next Generation Sequencing Market by country
13.5.2.2 Africa Next Generation Sequencing Market by Product & Service
13.5.2.3 Africa Next Generation Sequencing Market by Technology
13.5.2.4 Africa Next Generation Sequencing Market by Application
13.5.2.5 Africa Next Generation Sequencing Market by End User
13.5.2.6 Nigeria
13.5.2.6.1 Nigeria Next Generation Sequencing Market by Product & Service
13.5.2.6.2 Nigeria Next Generation Sequencing Market by Technology
13.5.2.6.3 Nigeria Next Generation Sequencing Market by Application
13.5.2.6.4 Nigeria Next Generation Sequencing Market by End User
13.5.2.7 South Africa
13.5.2.7.1 South Africa Next Generation Sequencing Market by Product & Service
13.5.2.7.2 South Africa Next Generation Sequencing Market by Technology
13.5.2.7.3 South Africa Next Generation Sequencing Market by Application
13.5.2.7.4 South Africa Next Generation Sequencing Market by End User
13.5.2.8 Rest of Africa
13.5.2.8.1 Rest of Africa Next Generation Sequencing Market by Product & Service
13.5.2.8.2 Rest of Africa Next Generation Sequencing Market by Technology
13.5.2.8.3 Rest of Africa Next Generation Sequencing Market by Application
13.5.2.8.4 Rest of Africa Next Generation Sequencing Market by End User
13.6. Latin America
13.6.1 Latin America Next Generation Sequencing Market by country
13.6.2 Latin America Next Generation Sequencing Market by Product & Service
13.6.3 Latin America Next Generation Sequencing Market by Technology
13.6.4 Latin America Next Generation Sequencing Market by Application
13.6.5 Latin America Next Generation Sequencing Market by End User
13.6.6 Brazil
13.6.6.1 Brazil Next Generation Sequencing Market by Product & Service
13.6.6.2 Brazil Next Generation Sequencing Market by Technology
13.6.6.3 Brazil Next Generation Sequencing Market by Application
13.6.6.4 Brazil Next Generation Sequencing Market by End User
13.6.7 Argentina
13.6.7.1 Argentina Next Generation Sequencing Market by Product & Service
13.6.7.2 Argentina Next Generation Sequencing Market by Technology
13.6.7.3 Argentina Next Generation Sequencing Market by Application
13.6.7.4 Argentina Next Generation Sequencing Market by End User
13.6.8 Colombia
13.6.8.1 Colombia Next Generation Sequencing Market by Product & Service
13.6.8.2 Colombia Next Generation Sequencing Market by Technology
13.6.8.3 Colombia Next Generation Sequencing Market by Application
13.6.8.4 Colombia Next Generation Sequencing Market by End User
13.6.9 Rest of Latin America
13.6.9.1 Rest of Latin America Next Generation Sequencing Market by Product & Service
13.6.9.2 Rest of Latin America Next Generation Sequencing Market by Technology
13.6.9.3 Rest of Latin America Next Generation Sequencing Market by Application
13.6.9.4 Rest of Latin America Next Generation Sequencing Market by End User
14. Company Profile
14.1 Illumina
14.1.1 Company Overview
14.1.2 Financials
14.1.3 Product & Services/ Services Offered
14.1.4 SWOT Analysis
14.1.5 The SNS View
14.2 F. Hoffman-La Roche Ltd.
14.2.1 Company Overview
14.2.2 Financials
14.2.3 Product & Services/ Services Offered
14.2.4 SWOT Analysis
14.2.5 The SNS View
14.3 QIAGEN
14.3.1 Company Overview
14.3.2 Financials
14.3.3 Product & Services/ Services Offered
14.3.4 SWOT Analysis
14.3.5 The SNS View
14.4 Thermo Fisher Scientific Inc.
14.4 Company Overview
14.4.2 Financials
14.4.3 Product & Services/ Services Offered
14.4.4 SWOT Analysis
14.4.5 The SNS View
14.5 Bio-Rad Laboratories Inc.
14.5.1 Company Overview
14.5.2 Financials
14.5.3 Product & Services/ Services Offered
14.5.4 SWOT Analysis
14.5.5 The SNS View
14.6 Oxford Nanopore Technologies
14.6.1 Company Overview
14.6.2 Financials
14.6.3 Product & Services/ Services Offered
14.6.4 SWOT Analysis
14.6.5 The SNS View
14.7 PierianDx
14.7.1 Company Overview
14.7.2 Financials
14.7.3 Product & Services/ Services Offered
14.7.4 SWOT Analysis
14.7.5 The SNS View
14.8 Genomatix GmbH
14.8.1 Company Overview
14.8.2 Financials
14.8.3 Products/ Services Offered
14.8.4 SWOT Analysis
14.8.5 The SNS View
14.9 DNASTAR, Inc.
14.9.1 Company Overview
14.9.2 Financials
14.9.3 Products/ Services Offered
14.9.4 SWOT Analysis
14.9.5 The SNS View
14.10 Perkin Elmer, Inc.
14.10.1 Company Overview
14.10.2 Financials
14.10.3 Products/ Services Offered
14.10.4 SWOT Analysis
14.10.5 The SNS View
14.11 Eurofins GATC Biotech GmbH
14.11.1 Company Overview
14.11.2 Financials
14.11.3 Products/ Services Offered
14.11.4 SWOT Analysis
14.11.5 The SNS View
14.12 BGI
14.12.1 Company Overview
14.12.2 Financials
14.12.3 Products/ Services Offered
14.12.4 SWOT Analysis
14.12.5 The SNS View
14.13 Others
15. Competitive Landscape
15.1 Competitive Bench marking
15.2 Market Share Analysis
15.3 Recent Developments
15.3.1 Industry News
15.3.2 Company News
15.3.3 Mergers & Acquisitions
16. USE Cases and Best Practices
17. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
In 2022, The Coronary Stent Market size amounted to USD 9.51 Billion & is estimated to reach USD 12.81 Billion by 2030 and increase at a compound annual growth rate of 3.8% between 2023 and 2030.
The Teleradiology Market Size was valued at USD 5.33 billion in 2022, and is expected to reach USD 15.33 billion by 2030, and grow at a CAGR of 14.1% over the forecast period 2023-2030.
The Central Nervous System Treatment Market size was valued at USD 97.20 Bn in 2022 and is expected to reach USD 196.53 Bn by 2030 and grow at a CAGR of 9.2% over the forecast period of 2023-2030.
The Blood Screening Market size was estimated USD 2.6 billion in 2022 and is expected to reach USD 4.99 billion By 2030 at a CAGR of 8.5 % during the forecast period of 2023-2030.
The Rotator Cuff Injury Treatment Market size was estimated USD 989.3 million in 2022 and is expected to reach USD 1439.5 million by 2030 at a CAGR of 4.8% during the forecast period of 2023-2030.
The Healthcare Payer Services Market Size was valued at USD 62.67 billion in 2022 and is expected to reach USD 111.7 billion by 2030 and grow at a CAGR of 7.5% over the forecast period 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2023 All Rights Reserved by SNS Insider Pvt Ltd
